NanoVibronix Issues Letter to Stockholders
We are focused on several areas that we believe will have a substantial impact on our growth and product adoption.
- We are focused on several areas that we believe will have a substantial impact on our growth and product adoption.
- A driving factor in our increased revenues was increased sales to customers using the Veterans’ Health System and worker’s compensation plans.
- On our balance sheet for the period ended December 31, 2023, we had $3.3 million of cash and inventory of $2.7 million.
- CMS invited NanoVibronix to a public meeting to present its findings and to answer CMS’s questions, which was held June 1, 2023.